CN110536685A - Sox18蛋白活性的抑制剂用于治疗血管生成相关疾病和/或淋巴管生成相关疾病 - Google Patents

Sox18蛋白活性的抑制剂用于治疗血管生成相关疾病和/或淋巴管生成相关疾病 Download PDF

Info

Publication number
CN110536685A
CN110536685A CN201780086511.1A CN201780086511A CN110536685A CN 110536685 A CN110536685 A CN 110536685A CN 201780086511 A CN201780086511 A CN 201780086511A CN 110536685 A CN110536685 A CN 110536685A
Authority
CN
China
Prior art keywords
sox18
protein
cancer
disorder
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780086511.1A
Other languages
English (en)
Chinese (zh)
Inventor
M·弗兰克斯
J·朱格
J·奥沃曼
S·K·玛米德雅拉
A·A·萨利姆
F·R·方丹
M·A·库伯
R·J·卡彭
A·A·B·罗伯特森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016905362A external-priority patent/AU2016905362A0/en
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Publication of CN110536685A publication Critical patent/CN110536685A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/66—Polycyclic acids with unsaturation outside the aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/15—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings, e.g. phenylphenol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/33—Polycyclic acids
    • C07C63/331—Polycyclic acids with all carboxyl groups bound to non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780086511.1A 2016-12-23 2017-12-21 Sox18蛋白活性的抑制剂用于治疗血管生成相关疾病和/或淋巴管生成相关疾病 Pending CN110536685A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016905362A AU2016905362A0 (en) 2016-12-23 Compounds and use thereof in methods of treatment
AU2016905362 2016-12-23
PCT/AU2017/051439 WO2018112545A1 (en) 2016-12-23 2017-12-21 Inhibitors of sox18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases

Publications (1)

Publication Number Publication Date
CN110536685A true CN110536685A (zh) 2019-12-03

Family

ID=62624141

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780086511.1A Pending CN110536685A (zh) 2016-12-23 2017-12-21 Sox18蛋白活性的抑制剂用于治疗血管生成相关疾病和/或淋巴管生成相关疾病

Country Status (8)

Country Link
US (3) US11434190B2 (cg-RX-API-DMAC7.html)
EP (1) EP3558293A4 (cg-RX-API-DMAC7.html)
JP (2) JP7579057B2 (cg-RX-API-DMAC7.html)
KR (1) KR102572077B1 (cg-RX-API-DMAC7.html)
CN (1) CN110536685A (cg-RX-API-DMAC7.html)
AU (1) AU2017383102B2 (cg-RX-API-DMAC7.html)
CA (1) CA3048040A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018112545A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115579087A (zh) * 2022-10-21 2023-01-06 贵州大学 筛选丹参和川芎活性成分为组织因子抑制剂的方法及用途
CN118834915A (zh) * 2024-08-15 2024-10-25 扬州大学 一种在羊毛乳头细胞中稳定过表达的sox18慢病毒重组标签载体的构建及应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102572077B1 (ko) * 2016-12-23 2023-08-29 더 유니버서티 어브 퀸슬랜드 혈관신생- 및/또는 림프관신생-관련 질환을 치료하기 위한 sox18 단백질 활성의 억제제
CN110143941B (zh) * 2019-06-04 2021-05-25 北京四环制药有限公司 一种巴罗萨韦玛波酯中间体的合成方法
US20230355557A1 (en) * 2020-08-26 2023-11-09 Gertrude Biomedical Pty Ltd Antiviral sox inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074753A1 (de) * 2000-03-30 2001-10-11 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Synthetische derivate von lunularsäure, arzneimittel enthaltend diese verbindungen, verfahren zur herstellung der lunularsäurederivate sowie deren verwendung

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01503303A (ja) * 1987-05-19 1989-11-09 フアイソンズ・ピーエルシー 化合物
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
WO2005005601A2 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
ITRM20030355A1 (it) 2003-07-18 2005-01-19 Sigma Tau Ind Farmaceuti Composti ad attivita' citotossica derivati della combretastatina.
UA94724C2 (en) * 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
CN101062043B (zh) * 2006-04-30 2011-06-08 浙江天皇药业有限公司 3,4,5,4'-四甲氧基二苯乙烷-3’-o-磷酸二钠在抗肿瘤及其转移药物的应用
CN101235003B (zh) * 2007-02-01 2010-09-15 浙江赛尔生物医学研究有限公司 3,4,5,4'-四甲氧基-α,β-二苯乙烷-3'-O-硫酸酯钠盐及其应用
MX2011003881A (es) * 2008-10-13 2011-05-03 Novartis Ag Derivados del acido salicilico que son inhibidores de la actividad de farnesil-pirofosfato-sintasa.
CN110386876A (zh) * 2010-03-24 2019-10-29 俄亥俄州立大学 用于葡萄糖转运抑制的组合物和方法
CN102050759A (zh) * 2010-12-09 2011-05-11 江苏天晟药业有限公司 白藜芦醇酰胺类衍生物及其制备方法
AU2014223548A1 (en) * 2013-02-26 2015-10-15 Triact Therapeutics, Inc. Cancer therapy
US10076574B2 (en) 2013-10-25 2018-09-18 Wayne State University Methods, systems and compositions relating to cell conversion via protein-induced in-vivo cell reprogramming
KR102572077B1 (ko) * 2016-12-23 2023-08-29 더 유니버서티 어브 퀸슬랜드 혈관신생- 및/또는 림프관신생-관련 질환을 치료하기 위한 sox18 단백질 활성의 억제제
US20230355557A1 (en) * 2020-08-26 2023-11-09 Gertrude Biomedical Pty Ltd Antiviral sox inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074753A1 (de) * 2000-03-30 2001-10-11 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Synthetische derivate von lunularsäure, arzneimittel enthaltend diese verbindungen, verfahren zur herstellung der lunularsäurederivate sowie deren verwendung

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115579087A (zh) * 2022-10-21 2023-01-06 贵州大学 筛选丹参和川芎活性成分为组织因子抑制剂的方法及用途
CN115579087B (zh) * 2022-10-21 2026-01-02 贵州大学 筛选丹参和川芎活性成分为组织因子抑制剂的方法及用途
CN118834915A (zh) * 2024-08-15 2024-10-25 扬州大学 一种在羊毛乳头细胞中稳定过表达的sox18慢病毒重组标签载体的构建及应用

Also Published As

Publication number Publication date
AU2017383102B2 (en) 2023-05-11
US12410116B2 (en) 2025-09-09
US11434190B2 (en) 2022-09-06
EP3558293A1 (en) 2019-10-30
JP7579057B2 (ja) 2024-11-07
KR102572077B1 (ko) 2023-08-29
EP3558293A4 (en) 2020-10-28
US20240002326A1 (en) 2024-01-04
AU2017383102A1 (en) 2019-08-01
KR20190105018A (ko) 2019-09-11
CA3048040A1 (en) 2018-06-28
JP2023011613A (ja) 2023-01-24
US20190337880A1 (en) 2019-11-07
WO2018112545A1 (en) 2018-06-28
JP2020506884A (ja) 2020-03-05
US20230100768A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
US12410116B2 (en) Compounds and use thereof in methods of treatment
Stanley et al. Dysregulation and therapeutic targeting of RNA splicing in cancer
Beyer et al. β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis
Chapeau et al. Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers
Holden et al. Small molecule dysregulation of TEAD lipidation induces a dominant-negative inhibition of hippo pathway signaling
KR102587175B1 (ko) 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
Bouché et al. Benzoisoquinolinediones as potent and selective inhibitors of BRPF2 and TAF1/TAF1L bromodomains
An et al. A-Raf: A new star of the family of raf kinases
KR20140026624A (ko) 노치 경로 신호전달 억제제 화합물
JP2002514599A (ja) ピリジニルイミダゾールによるプロテインキナーゼの阻害
JP2019508496A (ja) 癌の治療法のためのｔａｆ１阻害剤
Zheng et al. Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2–p53 interaction
Shukla et al. Mutations of RNA splicing factors in hematological malignancies
Du et al. Discovery and synthesis of a naturally derived protein kinase inhibitor that selectively inhibits distinct classes of serine/threonine kinases
Sun et al. Structure-guided discovery of potent and selective CLK2 inhibitors for the treatment of knee osteoarthritis
Uguen et al. Tudor-Containing Methyl-Lysine and Methyl-Arginine Reader Proteins: Disease Implications and Chemical Tool Development
WO2025064918A1 (en) First-in-class phospho-brd4 inhibitors
Bollag Setting up a kinase discovery and development project
Miller The development of small molecule inhibitors for fibrosis drug discovery

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination